Skip to main content

Table 1 The functions of m6A methyltransferases in drug and radiotherapy resistance

From: N6-methyladenosine methyltransferases: functions, regulation, and clinical potential

Therapy type Drug name Cancer Regulator Regulation Target References
Chemo-therapy Cisplatin Seminoma METTL3 PR TFAP2C [92]
Gastric cancer METTL3 PR ARHGAP5 [93]
NSCLC METTL3 ES FSP1 [94]
NKTCL WTAP PR DUSP6 [95]
Nasopharyngeal carcinoma METTL3 PR TRIM11 [43]
Oxaliplatin Colorectal cancer METTL3 PR P53/Sec62 [96]
Taxol Breast cancer METTL3 PR ERRγ [98]
Doxorubicin (adriamycin) Breast cancer METTL3 PR pri-microRNA-221-3p [100]
Anthracycline Breast cancer METTL3 PR ABCB1 [98]
Targeted therapy Everolimus Gastric tumors METTL3 ES pri-miR-17–92 [53]
Crizotinib NSCLC METTL3/WTAP PR c-MET [108]
Gefitinib NSCLC METTL3 PR METTL3-mediated Autophagy [110]
Lung Adenocarcinoma METTL3 PR c-MET [111]
Sorafenib HCC METTL14 PR HNF3γ [112]
HCC METTL3/14 PR circRNA-SORE [42]
HCC METTL3 ES FOXO3 [74]
Immuno therapy Anti-PD-1 Melanoma METTL3 (macrophages) PR SPRED2 [57]
Colorectal carcinoma/Melanoma METTL3/14 PR Stat1/Irf1 [117]
Radio-therapy γ-irradiation Glioblastoma METTL3 PR SOX2 [76]
X-ray Irradiation Hypopharyngeal Squamous cell carcinoma METTL3 PR circCUX1 [119]
  1. NSCLC non-small cell lung carcinoma, NKTCL nasal-type natural killer/T-cell lymphoma, HCC hepatocellular carcinoma, PR Promote resistance, ES Enhance sensitivity